The Citi analyst pointed out that despite the recent weak sentiment surrounding Apellis stocks, due to the European Union's non-approval of Syfovre and uncertainties regarding the strength of its U.S.

While Astellas’ Izervay and Apellis’ Syfovre battle for market share in geographic atrophy (GA) in the United States, both companies are struggling to reach patients in the indication in Europe.

The Citi analyst pointed out that despite the recent weak sentiment surrounding Apellis stocks, due to the European Union's non-approval of Syfovre and uncertainties regarding the strength of its ...

Pegcetacoplan is already approved in paroxysmal nocturnal hemoglobinuria (PNH) and geographic atrophy (GA) under the brand names Empaveli and Syfovre, respectively. Two days after Apellis’ data ...

Despite these promising developments, Archila remains cautious due to near-term challenges associated with Syfovre, another key product for Apellis. The growth dynamics of Syfovre are seen as a ...

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of deadlines, online calls, and meetings ...

and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email ...

and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email ...

An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models. Tips that distill complex financial data into concise, ...